Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
Clinical trial NCT05501054 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05501054
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-09
- Primary completion
- 2026-11-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.